PFE Aug 2024 32.000 call
- Reuters
UPDATE 1-Pfizer offers up to $250 mln to settle Zantac cancer lawsuits, FT reports
Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.
- Reuters
Pfizer offers up to $250 million to settle Zantac cancer lawsuits, FT reports
The drugmaker was set to pay between $200 million and $250 million in the settlement, the newspaper reported, citing two people briefed on the deal. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.
- Investor's Business Daily
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Pfizer stock is now above its key moving averages after reporting better-than-expected first-quarter sales. Is PFE stock a buy now?
